GHOST TREE CAPITAL LLC
Q4 2021 Form 13-F
NEW YORK, NEW YORK
CIK 0001595851
· CRD 167435
· SEC-registered investment adviser
$279.0M Reported Value Total
GHOST TREE CAPITAL, LLC reports 9 total accounts under management (AUM). There are 9 discretionary accounts valued at $576,414,823, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
3 funds
· $194.6M gross asset value
Hedge Fund: $194.6M
Source: Form ADV filed 2025-01-17
Reported value
$279.0M
Quarter over quarter
+2.0%
Holdings
43
Top-10 concentration
47.4%
Key People
Form ADV owners & control persons
David Young-Jae Kim
MANAGING PARTNER; OWNER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2021 13F record
Q4 2021 13F filing summary
| Period of report | December 31, 2021 |
|---|---|
| Filed | February 16, 2022 |
| Form | 13F-HR |
| Reported value | $279.0M |
| Positions | 43 |
| Change in reported value | -18.4% |
| New positions | 9 |
| Exited positions | 21 |
| Position turnover | 46.9% |
| Top-10 concentration | 47.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2024 13F
Filed Nov 14, 2024
|
51 | $331.0M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
59 | $319.3M |
|
Q1 2024 13F
Filed May 15, 2024
|
65 | $361.3M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
44 | $305.9M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
58 | $304.1M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
55 | $302.9M |
|
Q1 2023 13F
Filed May 15, 2023
|
52 | $338.3M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
35 | $234.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
35 | $356.3M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
29 | $192.0M |
|
Q1 2022 13F
Filed May 16, 2022
|
39 | $460.8M |
|
Q4 2021 13F
Filed Feb 16, 2022
|
43 | $279.0M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
55 | $342.0M |
|
Q2 2021 13F
Filed Aug 11, 2021
|
49 | $363.8M |
|
Q1 2021 13F
Filed May 14, 2021
|
46 | $425.5M |
|
Q4 2020 13F
Filed Feb 16, 2021
|
40 | $448.8M |
|
Q3 2020 13F
Filed Nov 16, 2020
|
45 | $346.0M |
|
Q2 2020 13F
Filed Aug 14, 2020
|
39 | $379.0M |
|
Q1 2020 13F
Filed May 15, 2020
|
42 | $377.0M |
|
Q4 2019 13F
Filed Feb 14, 2020
|
45 | $525.1M |
24 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q4 2021
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A/S | $25.6M | 9.16% |
| 2 | APLS APELLIS PHARMACEUTICALS INC | $15.4M | 5.51% |
| 3 | COGT COGENT BIOSCIENCES INC | $14.6M | 5.23% |
| 4 | CLDX CELLDEX THERAPEUTICS INC NEW | $13.5M | 4.85% |
| 5 | RAPT RAPT THERAPEUTICS INC | $12.9M | 4.61% |
| 6 | MRUS MERUS N V | $11.1M | 3.99% |
| 7 | ISEE IVERIC BIO INC | $10.5M | 3.74% |
| 8 | VRDN VIRIDIAN THERAPEUTICS INC | $9.9M | 3.54% |
| 9 | IOVA C IOVANCE BIOTHERAPEUTICS INC | $9.5M | 3.42% |
| 10 | RCKT ROCKET PHARMACEUTICALS INC | $9.3M | 3.32% |
| 11 | ARVN ARVINAS INC | $9.0M | 3.24% |
| 12 | SRPT SAREPTA THERAPEUTICS INC | $9.0M | 3.23% |
| 13 | BLU P BELLUS HEALTH INC NEW | $7.2M | 2.57% |
| 14 | ZNTL ZENTALIS PHARMACEUTICALS INC | $6.7M | 2.41% |
| 15 | SNDX SYNDAX PHARMACEUTICALS INC | $6.6M | 2.35% |
| 16 | PCVX VAXCYTE INC | $5.9M | 2.13% |
| 17 | FOLD AMICUS THERAPEUTICS INC | $5.8M | 2.07% |
| 18 | SRRA SIERRA ONCOLOGY INC | $5.4M | 1.95% |
| 19 | ALNY ALNYLAM PHARMACEUTICALS INC | $5.1M | 1.82% |
| 20 | VRNA VERONA PHARMA PLC | $5.0M | 1.81% |
Values as reported on the Q4 2021 Form 13F. Every position is in the holdings table below.